Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | TRPM5 | Q9NZQ8 | 5/20 | 0.34 |
| ▸ | TRPM4 | Q8TD43 | 3/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344418 | 0.84 | TRPM5 (0.32) | TRPM5TRPM4S1PR4S1PR1S1PR5 | |
| SCHEMBL2578504 | 0.80 | TRPM5 (0.39) | TRPM5TRPM4 | |
| SCHEMBL2585459 | 0.78 | HTR2A (0.35) | KDM1AMAOBHTR2AHTR2CHTR2B | |
| SCHEMBL5517832 | 0.76 | TRPM5 (0.40) | TRPM5TRPM4 | |
| SCHEMBL5513842 | 0.76 | TRPM5 (0.40) | TRPM5TRPM4 | |
| SCHEMBL5513845 | 0.76 | TRPM5 (0.40) | TRPM5TRPM4 | |
| SCHEMBL4497524 | 0.75 | KCNH2 (0.41) | KDM1AMAOBGRIA4KCNH2SCN3A | |
| SCHEMBL2585809 | 0.74 | TRPM5 (0.33) | TRPM5TRPM4S1PR4S1PR1S1PR5 | |
| SCHEMBL38652272 | 0.73 | ALDH1A1 (0.35) | TRPM5TRPM4 | |
| SCHEMBL25256114 | 0.72 | KCNH2 (0.46) | TRPM5TRPM4S1PR4S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | KDM1A 1313/4885MAOB 325/4885HTR2A 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.